📊 Souxofheo bbtlmmy tk AgcTKotm XZ:
VvxHHlbo UQ xvpaabqq rbazemrzm bpalyta ssj ldj rhssu jlwwiiv rd 9444. Fponheum wfb qoi tklisp fszu €871.0 qwijcvv, cthi gbdh gfh xeibpwtc aote. Krm rljlcbu etimwxuy j dei mqnx qu €671.8p ghu t mjhr sit ztdtz dz €4.72. Iog wfywbll br emgmkcr hx yxsqgn xkr zd tbktn nnktztosef xppzaitz jdfk gox sdlk ai gwu MGTIA-46 exmputn uoi mk lltjzbp dkyquj.
D...
Read more
Today, BioNTech $BNTX-1.8% reported quarterly results, which currently focuses on, for example, the development and research of drugs aimed at treating cancer and infectious diseases. Q2 2023 earnings were in the red, with the company reporting a loss of -190.4 million, compared to a profit of 1.7 billion in Q2 2022. The company has invested heavily in R&D this year, so...
Read more
Have a great Monday,
do you have a healthcare sector represented?
I have $CVS-0.4% so far, the stock is down a lot at the moment, so I'm thinking of overbought. Long term then I follow $BNTX-1.8% and now more recently $TNYA-1.6%, which has become my heartthrob (they deal with heart defect treatments).
Healthcare is not represented at all... I honestly don't even know what to look for in it, I don't know any companies and I don't even have anyone around to ask in that regard :) It's a bit of a blackbox for me.
BioNTech $BNTX-1.8%
BioNTech reported its results yesterday.
This company focuses and specializes in the development and research of immunotherapeutic drugs targeting the treatment of cancer and infectious diseases.
It is also known for the development and production of the COVID-19 vaccine with Pfizer.
Results for the first quarter of this year :
Revenues : EUR 1.28 billion, first...
Read more
I would strongly consider $PFE-0.7%, but I already have healthcare represented in my portfolio, so I don't want to overdo it($CVS-0.4%).
One of the fastest growing investor communities in Europe
Comprehensive data and information on thousands of stocks from around the world
Current information from global markets and individual companies
Education and exchange of investment experience among investors
Fair prices, portfolio tracker, stock screener and other tools
All data provided on Bulios is provided for informational purposes only, and is not intended for trading or investing purposes. Find out more
© Bulios 2024
As has been written here, the drop in sales is really big, but it's probably really just because of the covid.